Tavotek Biotherapeutics Announces Completion of Round A1 and A2 Financing with over $20 Million Dollars

LOWER GWYNEDD,Pennsylvania,March 22,2021 -- Tavotek Biotherapeutics announcesithasraised over $20Min Round A1 and Round A2 financing in the precedingtwomonths. YuanBioVenture Capitalled theA1finance round followed by OrizaHoldings,Ming BioVentures,and New AllianceCapital. Series A2 financing was jointlyinvestedby GF Xinde,CTSCapital,and Lanhu Capital. The tworoundsof financing will be used to accelerate the CMC production and IND filingsof three antibody drugs (Tavo111,Tavo103,and Tavo101) developed by the company based on itsTavoPrecise antibody platform. In addition,the funding will also be used to strengthen its bispecific / multispecific antibody pipelines and the development of multicyclic intracellular peptide (MIP) programs.

Tavotek Biotherapeutics,established in early2019,received its initial Round A investment from Apricot Capital. Tavotekis committed to using innovation to improvethe well-beingof patients with unmet medical needs. Presently,the company has two R&D centers: one in Lower Gwynedd,Pennsylvania and another in Suzhou,China. The core team members have decades of successful drug development experiences at multinational pharmaceutical firms (J&J,Abbott,GSK,Eli Lilly) which include many blockbuster drugs with annual sales of more than $1 billion.

Tavotek's research platformsare built uponthree breakthroughtechnologies: TavoSelect(an innovative Phage Display Library that generates conformational selective human full-length and single domain antibodies); TavoPrecise(a differentiatedengineering platformfor next generation tissue-specific biologics); and TavoMIP (a multicyclic peptide platformthat makes undruggabletargetsmore accessible).With thenewinfusionof capital,Tavotek is developing novel biologics targeting oncology and autoimmune diseases for patients. The company plans to bring three innovative antibodies into human clinical trials in late 2021 with another three assets to IND in 2022.

About Tavotek

Tavotek is a biopharmaceutical company focused on discovering,acquiring,developing,and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs. Tavotek has a rich pipeline of product candidates at various stages of development for cancer,autoimmune conditions,and inflammatory diseases. For more information,please visit www.tavotek.com.

Tavotek Contact:

Isa Fung,Investors and Media

Email: info@tavotek.com

View original content:/news-releases/tavotek-biotherapeutics-announces-completion-of-round-a1-and-a2-financing-with-over-20-million-dollars-301250774.html